We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antitumor Efficacy of Recombinant Human Interleukin-2 Combined with Sorafenib Against Mouse Renal Cell Carcinoma.
- Authors
Iguchi, Motofumi; Matsumoto, Mitsunobu; Hojo, Kanji; Wada, Toru; Matsuo, Yoshiyuki; Arimura, Akinori; Abe, Kenji
- Abstract
Objective: Recombinant human interleukin-2 (rhIL-2) has been clinically used in the treatment of renal cell carcinoma (RCC). Sorafenib, a multi-targeted kinase inhibitor, has been approved for RCC as well as IL-2. The purpose of this study was to evaluate the antitumor efficacy of IL-2 combined with sorafenib in three different murine renal cancer models using Renca cells.
- Publication
Japanese Journal of Clinical Oncology, 2009, Vol 39, Issue 5, p303
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyp021